Montelukast TEVA 10 mg 28 tablets

Composition:
active substance: montelukast sodium;
1 coated tablet contains 10 mg montelukast (as montelukast sodium);
excipients: lactose monohydrate, hydroxypropyl cellulose; corn starch; sodium starch (type A); magnesium stearate sodium lauryl sulfate; shell Opadry 20A23676 Yellow: hydroxypropyl methylcellulose, hypromellose, titanium dioxide (E 171), iron dioxide yellow (E172), iron oxide red (E 172).

Pharmacotherapeutic group:
Means for systemic use in obstructive respiratory diseases. Leukotriene receptor antagonists. ATX code R03D C03.

Indications:

• Additional treatment of persistent mild to moderate asthma, which is insufficiently controlled by inhaled corticosteroids, as well as in case of insufficient clinical control of asthma with short-acting β-agonists, used if necessary.
• Relief of symptoms of seasonal and perennial allergic rhinitis.
• Relieves symptoms of seasonal and allergic rhinitis in patients with bronchial asthma.
• For the prevention of exercise-induced asthmatic attacks.

Contraindications:
Hypersensitivity to montelukast or to any component of the drug. Age up to 15 years (for a dose of 10 mg).

Method of administration and dosage:
The recommended dose for patients (aged 15 years and older) is 10 mg (1 tablet) per day, in the evening. To relieve the symptoms of allergic rhinitis, the time of admission is selected individually.

General recommendations
The therapeutic effect of the drug on asthma control indicators is observed within 1 day. Montelukast-Teva can be used with or without food. Patients are advised to continue taking Montelukast-Teva, even if the manifestations of their asthma are under control, just as during an exacerbation.
It is not recommended to use drug simultaneously with other drugs containing the same active substance – montelukast.

Special patient groups
There is no need for dose adjustment for elderly patients or patients with renal insufficiency, or mild or moderate liver dysfunction. There is no data on the use of the drug in patients with severe liver dysfunction.
The dosage is the same for men and women.

Montelukast-Teva and other medications for asthma. Therapy can be added to the patient’s existing asthma regimen.

Inhaled corticosteroids
Can be used as an adjunctive treatment for patients in whom inhaled corticosteroids, together with short-acting β-agonists, used as needed, do not provide satisfactory clinical control of the disease.
Should not be abruptly substituted for inhaled corticosteroids